Fangzhou Jianke and Tencent Health Deepen Collaboration to Launch "AI + Chronic Disease Management" Solution, Activating a New Ecosystem of Industrial Synergy

On November 27, Fangzhou Pharmaceutical and Tencent Healthcare held a launch event for their “AI + Chronic Disease Management” solution, marking the entry of China’s chronic disease management sector into a new phase of development. Through this collaboration, the two parties will provide industry partners with end-to-end support spanning from technology validation and scenario implementation to large-scale deployment, injecting new momentum into the intelligent, compliant, and efficient development of the industry.

According to the introduction,Both partiesBased onDeep Accumulation in Their Respective Fields, to achieve complementary advantages. As a leading company in China, Fangzhou Pharmaceutical“AI + Chronic Disease Management"ServicesPlatform, with its innovative“AI+H2H (Hospital to Home) Smart HealthcareNewEcology”(hereinafter referred to as “AI+H2H Ecosystem”）, has established unique technological advantages in the field of chronic disease management, accumulatedPractical experience.Tencent CloudAs an industry-leading cloud service provider, inCloud Computing、Big Data, Artificial Intelligenceand other key technical fieldsOutstanding Strength. Both partiesStrategic Alliance, will be“AI+Chronic Disease Management"Number of DomainsIntelligenceHuaUpgradeProvide robust technical support.

Figure/“AI + Chronic Disease Management” Solution Launch Event

This industry-oriented solution is by no means a “castle in the air”; rather, it is grounded in Fangzhou Pharmaceutical’s proven practices in the field of “AI + chronic disease management,” with its value clearly demonstrated through the platform’s substantial business data.This YearOctober,Under the company's umbrellaPlatform AI Feature Trial Users Surge Significantly Month-over-Month2.4 times, demonstrating strong growth momentum.

In specific application scenarios, AI technology demonstrates remarkable precision in addressing users' genuine pain points. Taking the "Report Interpretation" feature of the Jianke Doctor app as an example, this function accurately targets the common challenge patients face in understanding their medical test reports.Following the launch of this feature, the user inquiry rate and the number of one-on-one conversations increased significantly, indicating that the AI functionality has successfully established user trust.

While AI capabilities have significantly enhanced service efficiency, Fangzhou Pharmaceutical has implemented multiple security safeguards at the technical infrastructure level to ensure reliable application in the highly sensitive healthcare sector.ForPotential Issues of Large Language Models in Professional Medical Scenarios“Hallucination”risks, the technical team employs measures such as knowledge base optimization, model supervision, and compliance upgrades to mostMinimize Risks to the Greatest Extent。

These achievements are attributable to Fangzhou Pharmaceutical’s continuous advancement of its AI+H2H ecosystem strategy.This ecosystem is centered around a self-developed large language model.Intelligent Engine, deeply integrating AI technology into business processes to form a coverage ofChronic DiseasesManage a closed-loop service system covering the entire lifecycle.Within this system, the AI Health Assistant provides 24/7 services including health consultations, knowledge Q&A, report interpretation, and intelligent triage; the AI Medication Assistant supports practical features such as photo-based medication identification; and the AI Content Creation Assistant empowers professional content production through functionalities like video profile AI analysis, AI script generation, and AI-powered remixing, thereby efficiently breaking down information barriers between doctors and patients.

Building on the proven success of its AI+H2H ecosystem, Fangzhou Pharmaceutical has further deepened its strategic partnership with Tencent Healthcare, committed to transforming validated AI capabilities into solutions that empower the entire industry.

Building on its proven technical achievements and business value in the field of “AI + Chronic Disease Management,” Fangzhou Pharmaceutical and Tencent Healthcare have further deepened their collaboration to jointly launch an industry-oriented “AI + Chronic Disease Management” solution,aims toProviding end-to-end support for industry partners, from technical validation to large-scale implementation. The plan willFangzhou Pharmaceutical’s AI capabilities accumulated in vertical scenarios,with Tencent Healthcare's leading fullOmnidirectional Service CapabilityDeep Integration,EmpowerIndustry PartnersAchieving Secure, Efficient, and Compliant Digital IntelligenceUpgrade。

This solution is built on a robust technical foundation: Fangzhou Pharmaceutical has established its large language model (LLM) base by leveraging the Tencent Healthcare TI Platform, utilizing elastic computing power and one-stop tools for training, evaluation, and deployment to achieve efficient fine-tuning and continuous optimization of the model. Furthermore, by integrating the Tencent Healthcare Vector Database—which boasts storage capacity for hundreds of billions of professional knowledge entries—with a Retrieval-Augmented Generation (RAG) architecture, the system enables millisecond-level semantic retrieval, significantly enhancing the accuracy and reliability of content generation. In terms of critical security and compliance, the company has implemented refined security policies tailored to medical scenarios by adopting the Tencent Healthcare Agent Security WAF, comprehensively safeguarding agent access pathways and sensitive data security, thereby helping business operations meet regulatory compliance requirements.

At the application level, Fangzhou Pharmaceutical’s mature technologies and Tencent Healthcare’s underlying infrastructure work in close synergy to ensure the efficient development and agile iteration of multi-scenario AI agents, thereby driving steady improvements in service quality and operational efficiency.

The newly launched solution deeply integrates the core strengths of both parties: Fangzhou Pharmaceutical contributes its profound understanding of internet medical service scenarios and professional model capabilities, while Tencent Healthcare provides stable, secure, and efficient technical infrastructure. Jointly implemented by both parties, this solution combines medical expertise with industrial-grade reliability, facilitating the large-scale application of AI technology in healthcare and empowering the industry to achieve high-quality digital transformation.

This collaboration represents not only a systematic export of technical capabilities, but also“AI + Healthcare”An Important Exploration of the Deep Integration Model.Recently, the National Health Commission and four other departments issued the “Implementation Opinions on Promoting and Standardizing the Development of ‘AI + Healthcare’ Applications.” Against this policy backdrop, AI in healthcare is gradually becoming a vital component of foundational public welfare initiatives. The collaboration between Fangzhou Pharmaceutical and Tencent Healthcare represents a significant practice in responding to policy calls and fostering the healthy development of the AI healthcare industry.

Looking ahead, Fangzhou Pharmaceutical will continue to prioritize technological innovation as its core driving force, deepen collaboration with Tencent Healthcare and other industry partners, and promote the development of chronic disease management services toward greater efficiency, precision, and accessibility through technological innovation and ecosystem co-construction. By contributing innovative strength to the realization of the “Healthy China 2030” strategic goals, we aim to jointly usher in a new chapter of smart healthcare with all stakeholders in the industry.